☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
P-IIIa
Novo Nordisk Reports Results of Semaglutide from P-IIIa STEP 1 Trial in Patients with Obesity
May 14, 2021
Novo Nordisk to Initiate P-IIIa Study for Oral Semaglutide to Treat Obesity
April 22, 2021
Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in P-IIIa Dupixent Eosinophilic Esophagitis Study for EoE
May 25, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
